D3 podtip dopaminskog receptora inhibira adenilil ciklazu putem inhibicije G proteina. Ovaj receptor je izražen u filogenetički starijim regionima mozga, što sugeriše da on ima ulogu u kognitivnim i emocionim funkcijama. On je meta za lekove kojima se tretira šizofrenija, addikcija, i Parkinsonova bolest[3] . Alternativno splajsovanje ovog gena proizvodi višestruke transkriptne varijante koje mogu da koriraju različite izoforme, mada neke varijante mogu da budu bez funkcije.[2]
Brojni neselektivni lekovi na recept se vezuju za D3 receptor. Među njima su neki od novijih dopaminskih agonista koji se koriste za lečenje Parkinsonove bolesti, npr. pramipeksol i ropinirol, koji se takođe vezuju za D2 i nemaju jaku selektivnost.
PF-219,061 ((R)-3-(4-Propilmorfolin-2-il)fenol): >1000-puta funkcionalna (efikasnost) selektivnost u odnosu na D2[6]
jedinjenje R,R-16: 250x selektivnost vezivanja u odnosu na D2[7]
trans-N4-[4-(2,3-Dihlorofenil)-1-piperazinil]cikloheksil3-metoksibenzamid, pun agonist, > 200-puta selektivniji u odnosu na D4, D2, 5-HT1A, i α1-receptore[8]
↑Joyce, JN; Millan, MJ (2007). „Dopamine D3 receptor agonists for protection and repair in Parkinson's disease.”. Current opinion in pharmacology7 (1): 100–5. PMID17174156.
↑Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S (2007). „Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route”. Bioorg. Med. Chem. Lett.17 (24): 6691–6. DOI:10.1016/j.bmcl.2007.10.059. PMID17976986.
↑Peglion JL, Poitevin C, La Cour CM, Dupuis D, Millan MJ (2009). „Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors”. Bioorg. Med. Chem. Lett.19 (8): 2133–8. DOI:10.1016/j.bmcl.2009.03.015. PMID19324548.
↑Leopoldo M, Lacivita E, Colabufo NA, Berardi F, Perrone R (2006). „Synthesis and binding profile of constrained analogues of N-[4-(4-arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D3 receptor ligands”. J. Pharm. Pharmacol.58 (2): 209–18. DOI:10.1211/jpp.58.2.0008. PMID16451749.
↑Biswas S, Zhang S, Fernandez F, Ghosh B, Zhen J, Kuzhikandathil E, Reith ME, Dutta AK (2008). „Further structure-activity relationships study of hybrid 7[2-(4-phenylpiperazin-1-yl)ethyl]propylamino5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action”. J. Med. Chem.51 (1): 101–17. DOI:10.1021/jm070860r. PMID18072730.
↑Dörfler M, Tschammer N, Hamperl K, Hübner H, Gmeiner P (2008). „Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies”. J. Med. Chem.51 (21): 6829–38. DOI:10.1021/jm800895v. PMID18834111.
↑ 12,012,1Bettinetti L, Schlotter K, Hübner H, Gmeiner P (2002). „Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists”. J. Med. Chem.45 (21): 4594–7. DOI:10.1021/jm025558r. PMID12361386.
↑Cagnotto A, Parotti L, Mennini T (October 1996). „In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study”. Eur. J. Pharmacol.313 (1-2): 63–7. DOI:10.1016/0014-2999(96)00503-1. PMID8905329.
↑Grundt P, Carlson EE, Cao J, et al. Novel heterocyclic trans olefin analogues of N4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl.arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor |journal=J. Med. Chem. |volume=48 |issue=3 |pages=839–48 |year=2005 |pmid=15689168 |doi=10.1021/jm049465g |url=}}
↑Xi ZX, Gardner EL (2007). „Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction”. CNS Drug Reviews13 (2): 240–59. DOI:10.1111/j.1527-3458.2007.00013.x. PMID17627675.
↑Griffon, Nathalie; Jeanneteau Freddy, Prieur Fanny, Diaz Jorge, Sokoloff Pierre (September 2003). „CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors”. Brain Res. Mol. Brain Res. (Netherlands) 117 (1): 47–57. DOI:10.1016/S0169-328X(03)00283-3. ISSN0169-328X. PMID14499480.
↑Binda, Alicia V; Kabbani Nadine, Lin Ridwan, Levenson Robert (September 2002). „D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N”. Mol. Pharmacol. (United States) 62 (3): 507–13. DOI:10.1124/mol.62.3.507. ISSN0026-895X. PMID12181426.
Sokoloff P, Giros B, Martres MP, et al. (1990). „Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.”. Nature347 (6289): 146–51. DOI:10.1038/347146a0. PMID1975644.
Giros B, Martres MP, Sokoloff P, Schwartz JC (1991). „[Gene cloning of human dopaminergic D3 receptor and identification of its chromosome]”. C. R. Acad. Sci. III, Sci. Vie311 (13): 501–8. PMID2129115.
Liu K, Bergson C, Levenson R, Schmauss C (1994). „On the origin of mRNA encoding the truncated dopamine D3-type receptor D3nf and detection of D3nf-like immunoreactivity in human brain.”. J. Biol. Chem.269 (46): 29220–6. PMID7961889.
Staley JK, Mash DC (1996). „Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities.”. J. Neurosci.16 (19): 6100–6. PMID8815892.
Gulcher JR, Jónsson P, Kong A, et al. (1997). „Mapping of a familial essential tremor gene, FET1, to chromosome 3q13.”. Nat. Genet.17 (1): 84–7. DOI:10.1038/ng0997-84. PMID9288103.
Oldenhof J, Vickery R, Anafi M, et al. (1998). „SH3 binding domains in the dopamine D4 receptor.”. Biochemistry37 (45): 15726–36. DOI:10.1021/bi981634. PMID9843378.
Cargill M, Altshuler D, Ireland J, et al. (1999). „Characterization of single-nucleotide polymorphisms in coding regions of human genes.”. Nat. Genet.22 (3): 231–8. DOI:10.1038/10290. PMID10391209.
Pilla M, Perachon S, Sautel F, et al. (1999). „Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.”. Nature400 (6742): 371–5. DOI:10.1038/22560. PMID10432116.
Soma M, Nakayama K, Rahmutula D, et al. (2002). „Ser9Gly polymorphism in the dopamine D3 receptor gene is not associated with essential hypertension in the Japanese.”. Med. Sci. Monit.8 (1): CR1–4. PMID11796958.
„Dopamine Receptors: D3”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Arhivirano iz originala na datum 2016-03-03.
.png)
